Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: Scientific evidence and expert opinion

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 1, 2014, Pages 1-8

  Martín Martínez, María A ^a   González Juanatey, Carlos ^b   Castañeda, Santos ^c   Llorca, Javier ^d,e   Ferraz Amaro, Iván ^f   Fernández Gutiérrez, Benjamín ^g   Díaz González, Federico ^a,f,h   González Gay, Miguel A ⁱ  

^a UNIDAD DE INVESTIGACIÓN   (Spain)

^b Hospital Lucus Augusti   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^f HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h UNIVERSIDAD DE LA LAGUNA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Atherosclerosis; Cardiovascular disease; Cardiovascular risk factors; Cardiovascular risk management; Guideline; Rheumatoid arthritis; Risk assessment

Indexed keywords

CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

ANKLE BRACHIAL INDEX; ATHEROSCLEROSIS; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY CALCIUM SCORE; DISEASE DURATION; ECHOGRAPHY; ENDOCRINOLOGIST; EVIDENCE BASED MEDICINE; EXERCISE; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; MEDICAL EXPERT; METABOLIC SYNDROME X; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; SMOKING CESSATION; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COMPLICATION; CONSENSUS; DISEASE MANAGEMENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CONSENSUS; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 84905269023     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.01.002     Document Type: Review

References (73)

1. Sangha O. Epidemiology of rheumatic diseases. Rheumatology (Oxford) 2000, 39(Suppl. 2):3-12.
2. Carmona L., Villaverde V., Hernandez-Garcia C., Ballina J., Gabriel R., Laffon A. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford) 2002, 41:88-95.
3. Ward M.M. Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs?. Arthritis Rheum 2001, 44:1467-1469.
4. Goodson N.J., Wiles N.J., Lunt M., Barrett E.M., Silman A.J., Symmons D.P. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002, 46:2010-2019.
5. Avina-Zubieta J.A., Choi H.K., Sadatsafavi M., Etminan M., Esdaile J.M., Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008, 59:1690-1697.
6. Avina-Zubieta J.A., Thomas J., Sadatsafavi M., Lehman A.J., Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012, 71:1524-1529.
7. Levy L., Fautrel B., Barnetche T., Schaeverbeke T. Incidence and risk of fatal myocardial infarction and stroke events in rheumatoid arthritis patients. A systematic review of the literature. Clin Exp Rheumatol 2008, 26:673-679.
8. Meune C., Touze E., Trinquart L., Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009, 48:1309-1313.
9. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005, 35:8-17.
10. Sodergren A., Karp K., Boman K., Eriksson C., Lundstrom E., Smedby T., et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010, 12:R158.
11. Kerola A.M., Kauppi M.J., Kerola T., Nieminen T.V. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?. Ann Rheum Dis 2012, 71:1606-1615.
12. del Rincon I.D., Williams K., Stern M.P., Freeman G.L., Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737-2745.
13. Dessein P.H., Joffe B.I., Veller M.G., Stevens B.A., Tobias M., Reddi K., et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005, 32:435-442.
14. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Lopez-Diaz M.J., Pineiro A., Garcia-Porrua C., Miranda-Filloy J.A., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007, 57:125-132.
15. Rodriguez-Rodriguez L., Gonzalez-Juanatey C., Palomino-Morales R., Vazquez-Rodriguez T.R., Miranda-Filloy J.A., Fernandez-Gutierrez B., et al. TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2011, 216:125-130.
16. Giles J.T., Post W.S., Blumenthal R.S., Polak J., Petri M., Gelber A.C., et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2011, 63:3216-3225.
17. Kitas G.D., Gabriel S.E. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011, 70:8-14.
18. Del Rincon I., Williams K., Stern M.P., Freeman G.L., O'Leary D.H., Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003, 48:1833-1840.
19. Dessein P.H., Joffe B.I. When is a patient with rheumatoid arthritis at risk for cardiovascular disease?. J Rheumatol 2006, 33:201-203.
20. Weiner D.E., Tighiouart H., Elsayed E.F., Griffith J.L., Salem D.N., Levey A.S., et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007, 50:217-224.
21. McEwan P., Williams J.E., Griffiths J.D., Bagust A., Peters J.R., Hopkinson P., et al. Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med 2004, 21:318-323.
22. Zgibor J.C., Piatt G.A., Ruppert K., Orchard T.J., Roberts M.S. Deficiencies of cardiovascular risk prediction models for type 1 diabetes. Diabetes Care 2006, 29:1860-1865.
23. Ruppert K., Roberts M.S., Orchard T.J., Zgibor J.C. Cardiovascular disease risk prediction in type 1 diabetes: accounting for the differences. Diabetes Res Clin Pract 2007, 78:234-237.
24. Crowson C.S., Nicola P.J., Kremers H.M., O'Fallon W.M., Therneau T.M., Jacobsen S.J., et al. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?. Arthritis Rheum 2005, 52:3039-3044.
25. Crowson C.S., Matteson E.L., Roger V.L., Therneau T.M., Gabriel S.E. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 2012, 110:420-424.
26. Peters M.J., Symmons D.P., McCarey D., Dijkmans B.A., Nicola P., Kvien T.K., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
27. Evans M.R., Escalante A., Battafarano D.F., Freeman G.L., O'Leary D.H., del Rincon I. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum 2011, 63:1211-1220.
28. Gonzalez-Juanatey C., Llorca J., Martin J., Gonzalez-Gay M.A. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 2009, 38:366-371.
29. Shekelle P., Eccles M.P., Grimshaw J.M., Woolf S.H. When should clinical guidelines be updated?. Br Med J 2001, 323:155-157.
30. Shekelle P.G., Ortiz E., Rhodes S., Morton S.C., Eccles M.P., Grimshaw J.M., et al. Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated?. J Am Med Assoc 2001, 286:1461-1467.
31. Grupo de trabajo sobre actualización de GPC. Actualización de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad y Política Social. Instituto Aragonés de Ciencias de la Salud-I+CS, 2009; Guías de Práctica Clínica en el SNS:I+CS, 2007/02-01.
32. Palda V.A., Davis D., Goldman J. A guide to the Canadian Medical Association handbook on clinical practice guidelines. Can Med Assoc J 2007, 177:1221-1226.
33. Network. SIG. SIGN 50: A guideline developers' handbook Edinburgh, 〈〉 2004 [accessed 15.7.12]. http://www.sign.ac.uk/pdf/sign50.pdf.
34. National Institute for Health and Clinical Excellence. The guidelines manual. London: National Institute for Health and Clinical Excellence; 〈http://www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/clinicalguidelinedevelopmentmethods/theguidelinesmanual2007/the_guidelines_manual_2007.jsp〉 2008 [accessed 15.7.12].
35. Scottish Intercollegiate Guidelines Network. Annex B: Key to evidence statements and grades of recommendations. Edinburgh: SIGN, 〈〉 2012 [accessed 28.6.12]. http://www.sign.ac.uk/guidelines/fulltext/50/annexb.html.
36. Rheumatoid arthritis: National Clinical Guideline for Management and Treatment in Adults 2009, National Collaborating Centre for Chronic Conditions (UK), Royal College of Physicians (UK), London.
37. Sociedad Española de Reumatología GUIPCAR : guía de práctica clínica para el manejo de la artritis reumatoide en España. Madrid: Sociedad Española de Reumatología; 〈http://www.ser.es/practicaClinica/GUIPCAR_2007/Menu0_Principal.php〉 2011 [accesed 20.6.12].
38. Greenland P., Alpert J.S., Beller G.A., Benjamin E.J., Budoff M.J., Fayad Z.A., et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010, 56:e50-103.
39. Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
40. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012, 33:1635-1701.
41. Lobos J.M., Royo-Bordonada M.A., Brotons C., Alvarez-Sala L., Armario P., Maiques A., et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish adaptation. Rev Clin Esp 2009, 209:279-302.
42. Micha R., Imamura F., Wyler Von Ballmoos M., Solomon D.H., Hernan M.A., Ridker P.M., et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011, 108:1362-1370.
43. Barnabe C., Martin B.J., Ghali W.A. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011, 63:522-529.
44. Sheridan S.L., Viera A.J., Krantz M.J., Ice C.L., Steinman L.E., Peters K.E., et al. The effect of giving global coronary risk information to adults: a systematic review. Arch Intern Med 2010, 170:230-239.
45. Peters S.A., den Ruijter H.M., Bots M.L., Moons K.G. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart 2012, 98:177-184.
46. Tyrrell P.N., Beyene J., Feldman B.M., McCrindle B.W., Silverman E.D., Bradley T.J. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2010, 30:1014-1026.
47. Vlachopoulos C., Aznaouridis K., Terentes-Printzios D., Ioakeimidis N., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with brachial-ankle elasticity index: a systematic review and meta-analysis. Hypertension 2012, 60:556-562.
48. Baillet A., Zeboulon N., Gossec L., Combescure C., Bodin L.A., Juvin R., et al. Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken) 2010, 62:984-992.
49. Ruyssen-Witrand A., Fautrel B., Saraux A., Le Loet X., Pham T. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011, 78:23-30.
50. van Sijl A.M., Peters M.J., Knol D.L., de Vet R.H., Sattar N., Dijkmans B.A., et al. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum 2011, 41:393-400.
51. Metsios G.S., Stavropoulos-Kalinoglou A., Veldhuijzen van Zanten J.J., Treharne G.J., Panoulas V.F., Douglas K.M., et al. Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. Rheumatology (Oxford) 2008, 47:239-248.
52. Westlake S.L., Colebatch A.N., Baird J., Curzen N., Kiely P., Quinn M., et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011, 50:518-531.
53. Westlake S.L., Colebatch A.N., Baird J., Kiely P., Quinn M., Choy E., et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010, 49:295-307.
54. Helfand M., Buckley D.I., Freeman M., Fu R., Rogers K., Fleming C., et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 2009, 151:496-507.
55. Finckh A., Courvoisier D.S., Pagano S., Bas S., Chevallier-Ruggeri P., Hochstrasser D., et al. Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores?. Arthritis Care Res (Hoboken) 2012, 64:817-825.
56. Gonzalez A., Icen M., Kremers H.M., Crowson C.S., Davis J.M., Therneau T.M., et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol 2008, 35:1009-1014.
57. Holmqvist M.E., Wedren S., Jacobsson L.T., Klareskog L., Nyberg F., Rantapaa-Dahlqvist S., et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med 2010, 268:578-585.
58. Innala L., Moller B., Ljung L., Magnusson S., Smedby T., Sodergren A., et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011, 13:R131.
59. Liang K.P., Kremers H.M., Crowson C.S., Snyder M.R., Therneau T.M., Roger V.L., et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009, 36:2462-2469.
60. Lopez-Longo F.J., Oliver-Minarro D., de la Torre I., Gonzalez-Diaz de Rabago E., Sanchez-Ramon S., Rodriguez-Mahou M., et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009, 61:419-424.
61. Myasoedova E., Crowson C.S., Nicola P.J., Maradit-Kremers H., Davis J.M., Roger V.L., et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 2011, 38:1601-1606.
62. Gomez-Vaquero C., Robustillo M., Narvaez J., Rodriguez-Moreno J., Gonzalez-Juanatey C., Llorca J., et al. Assessment of cardiovascular risk in rheumatoid arthritis: impact of the new EULAR recommendations on the score cardiovascular risk index. Clin Rheumatol 2012, 31:35-39.
63. Stein J.H., Korcarz C.E., Hurst R.T., Lonn E., Kendall C.B., Mohler E.R., et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008, 21:93-111. [quiz 89-90].
64. van den Oord S.C., Sijbrands E.J., ten Kate G.L., van Klaveren D., van Domburg R.T., van der Steen A.F., et al. Carotid intima-media thickness for cardiovascular risk assessment: systematic review and meta-analysis. Atherosclerosis 2013, 228:1-11.
65. van Sijl A.M., Peters M.J., Knol D.K., de Vet H.C., Gonzalez-Gay M.A., Smulders Y.M., et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 2011, 40:389-397.
66. Corrales A., Gonzalez-Juanatey C., Peiro M.E., Blanco R., Llorca J., Gonzalez-Gay M.A. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 2013, 72(Suppl 3):A597-A598. [Epub ahead of print].
67. Corrales A., Parra J.A., Gonzalez-Juanatey C., Rueda-Gotor J., Blanco R., Llorca J., et al. Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2013, 72:1764-1770.
68. Chung C.P., Oeser A., Solus J.F., Avalos I., Gebretsadik T., Shintani A., et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008, 196:756-763.
69. Daien C.I., Duny Y., Barnetche T., Daures J.P., Combe B., Morel J. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012, 71:862-868.
70. Antohe J.L., Bili A., Sartorius J.A., Kirchner H.L., Morris S.J., Dancea S., et al. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor alpha therapy. Arthritis Care Res (Hoboken) 2012, 64:215-221.
71. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Bohm M., Dickstein K., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847.
72. Bavry A.A., Khaliq A., Gong Y., Handberg E.M., Cooper-Dehoff R.M., Pepine C.J. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. Am J Med 2011, 124:614-620.
73. National Guideline C. Secondary prevention of coronary artery disease. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ). 〈〉 2009 [accessed 22.8.12]. http://www.guidelines.gov/content.aspx?id=16259.